<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04991038</url>
  </required_header>
  <id_info>
    <org_study_id>101903</org_study_id>
    <nct_id>NCT04991038</nct_id>
  </id_info>
  <brief_title>Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients</brief_title>
  <acronym>DAISE</acronym>
  <official_title>Prospective, Multi-center, Randomized Study to Compare the Safety and Efficacy of the DAISe Thrombectomy System and Stent Retrievers for Neurointervention in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MIVI Neuroscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MIVI Neuroscience, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the safety and efficacy of the DAISE to stent retrievers in the treatment of acute&#xD;
      ischemic stroke&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Outcome: Good Functional Outcome of Modified Rankin Score 0-2</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Outcome: Symptomatic intracranial hemorrhage</measure>
    <time_frame>24hrs post procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mTICI 2b-3 after randomized modality</measure>
    <time_frame>procedure after use of randomized device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTICI 2b-3 after first attempt with randomized modality</measure>
    <time_frame>procedure after first attempt with randomized device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTICI 2c-3 after randomized modality</measure>
    <time_frame>procedure after use of randomized device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTICI 2c-3 after the first attempt with randomized modality</measure>
    <time_frame>procedure after first attempt with randomized device</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTICI 2b-3 at end of the procedure</measure>
    <time_frame>procedure after all interventions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mTICI 2c-3 at end of the procedure</measure>
    <time_frame>procedure after all interventions</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Time</measure>
    <time_frame>procedure</time_frame>
    <description>Time from groin puncture to first successful revascularization devices as mTICI 2b-3 flow (as long as final mTICI 2b-3 is achieved)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of procedure and/or device related serious adverse events</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all intracranial hemorrhage at 24hrs</measure>
    <time_frame>24hrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of embolization to a new vascular territory (ENT) during procedure</measure>
    <time_frame>procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality at 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic/Stroke related mortality at 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcome assessment by PROMIS Global-10 at 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Stroke</condition>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke, Acute</condition>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>DAISe Thrombectomy Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical Thrombectomy with DAISe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stent Retriever</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mechanical Thrombectomy with TREVO or Solitaire Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DAISe Device</intervention_name>
    <description>Thrombectomy using the DAISE device</description>
    <arm_group_label>DAISe Thrombectomy Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trevo or Solitaire</intervention_name>
    <description>Thrombectomy using TREVO or Solitaire device</description>
    <arm_group_label>Stent Retriever</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and older&#xD;
&#xD;
          -  Pre-stroke independent functional status in activities of daily living with modified&#xD;
             Rankin Score 0-1&#xD;
&#xD;
          -  Patient presenting with a disabling stroke device as NIHSS ≥6&#xD;
&#xD;
          -  Thrombolytic therapy (IV tPA), if indicated/administered, was initiated within 3 hours&#xD;
             of onset/ last known well according to prescribed dosing.Endovascular treatment&#xD;
             intended to be initiated (groin puncture) &lt;24 hours from onset of symptoms or last&#xD;
             known well time.&#xD;
&#xD;
          -  Confirmed symptomatic large vessel occlusion of the intracranial internal carotid&#xD;
             artery, M1 or proximal M2 segment of the middle cerebral artery.&#xD;
&#xD;
          -  The following image criteria should also be met:&#xD;
&#xD;
        For Subjects 0-6hrs onset:&#xD;
&#xD;
          -  MRI Criterion: volume of diffusion restriction as assessed by automated core volume&#xD;
             software ≤50mL OR&#xD;
&#xD;
          -  CT Criterion: ASPECTS 6-10 on baseline CT or CTA-source images or, CPT as assessed by&#xD;
             automated core volume software ≤50mL&#xD;
&#xD;
        For subjects 6-24hrs onset:&#xD;
&#xD;
          -  ≤20mL Ischemic core volume if age &gt;80&#xD;
&#xD;
          -  ≤30mL Ischemic core volume if age &lt;80 and NIHSS 10-20&#xD;
&#xD;
          -  ≤50mL Ischemic core volume if age &lt;80 and NIHSS &gt;20&#xD;
&#xD;
          -  Signed informed consent from patient or legal authorized representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CT or MRI evidence of intracranial hemorrhage on presentation.&#xD;
&#xD;
          -  CT or MRI showing mass effect or intracranial tumor (meningioma &gt;2cm in diameter)&#xD;
&#xD;
          -  CT or MRI evidence of carotid dissection or complete cervical carotid occlusion&#xD;
             requiring a stent.&#xD;
&#xD;
          -  Previous stroke within the past 3 months.&#xD;
&#xD;
          -  Known arterial condition (proximal vessel stenosis or pre-existing stent) that would&#xD;
             prevent the study devices from reaching the target vessel and/or preclude safe&#xD;
             recovery of the study devices.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Severe contrast allergy or absolute contraindication to iodinated contrast.&#xD;
&#xD;
          -  Rapidly improving neurological status as determined by Investigator/Neurologist.&#xD;
&#xD;
          -  Renal failure/insufficiency with &gt;3.0 mg/dL creatinine prior to procedure.&#xD;
&#xD;
          -  Severe, sustained hypertension resistant to treatment (SBP&gt;185mmHg or DBP &gt;110mmHg)&#xD;
&#xD;
          -  Use of warfarin anticoagulation with International Normalized Ratio (INR) &gt;3.0 at the&#xD;
             time of the procedure or any known hemorrhagic or coagulation deficiency.&#xD;
&#xD;
          -  For patients who have received a direct thrombin inhibitor within the last 48hrs;&#xD;
             partial thromboplastin time (PTT) &gt; 2.0 times the normal prior to procedure.&#xD;
&#xD;
          -  Platelet count &lt; 50,000&#xD;
&#xD;
          -  Cerebral vasculitis or evidence of active systemic infection (including COVID-19)&#xD;
&#xD;
          -  Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.&#xD;
&#xD;
          -  Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular&#xD;
             territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).&#xD;
&#xD;
          -  Seizure due to stroke.&#xD;
&#xD;
          -  Clinical history, past imaging or clinical judgment suggests that the intracranial&#xD;
             occlusion is chronic.&#xD;
&#xD;
          -  Active participation in another study involving an investigational drug or device.&#xD;
&#xD;
          -  A severe or fatal comorbid illness that will prevent improvement or follow-up or that&#xD;
             will render the procedure unlikely to benefit the patient.&#xD;
&#xD;
          -  Unwillingness to complete follow up visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adnan Siddiqui, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UB/Kaleida Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Jankowitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>U Penn Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luvas Elijovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tennessee Health Sciences Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chris Pierzchalski</last_name>
    <phone>262-391-0954</phone>
    <email>cpierzchalski@mivineuro.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAISE</keyword>
  <keyword>thrombectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

